Reuters logo
Otonomy's ear disease drug fails late-stage study
August 30, 2017 / 11:16 AM / 3 months ago

Otonomy's ear disease drug fails late-stage study

Aug 30 (Reuters) - U.S. drugmaker Otonomy Inc said on Wednesday its drug to treat Ménière’s disease, a chronic disorder of the inner ear, missed the main goal in a late-stage study.

The drug, Otividex, was tested against a placebo in 165 patients, Otonomy said.

Ménière’s typically affects one ear, causing vertigo, a persistent ringing in the ear, and ultimately, permanent loss of hearing. The disease affects about 600,000 Americans. (Reporting by Natalie Grover in Bengaluru; Editing by Sai Sachin Ravikumar)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below